FDA Grants Priority Review to Cladribine Tablets
- Details
- Category: Merck Group
Merck KGaA announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS).
Lilly Reports Strong Second-Quarter 2010 Results
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) announced financial results for the second quarter of 2010. In the second quarter of 2010, worldwide total revenue was $5.749 billion, an increase of 9 percent compared with the second quarter of 2009.
Sanofi-aventis expresses concern over the approval of another version of enoxaparin sodium
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has reservations on approval by the U.S. Food and Drug Administration (FDA) of another version of enoxaparin sodium.
Sandoz leads the way with first generic version of 'gold standard' anti-thrombotic Lovenox®
- Details
- Category: Novartis
Sandoz announced the introduction of enoxaparin sodium injection, the first generic version of Lovenox®[1], in the US. Product shipment began immediately following approval by the US Food and Drug Administration (FDA).
Roche posts good half year results
- Details
- Category: Roche
The Roche Group posted strong operating results in the first half of 2010. Group sales grew by 5% in local currencies (3% in Swiss francs; 7% in US dollars) to 24.6 billion Swiss francs. The Pharmaceuticals Division increased its sales by 4% in local currencies (1% in Swiss francs; 6% in US dollars) to 19.4 billion Swiss francs.
Pfizer to Offer Free Public Access to Mental Health Assessment Tools
- Details
- Category: Pfizer
As part of its commitment to improving the quality of patient care, Pfizer (NYSE: PFE) will make available assessment scales used by physicians and others in the healthcare community to support the evaluation and diagnosis of patients suffering from certain mental disorders.
Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data and Double-Digit EPS Growth
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) reported results for the second quarter of 2010 which featured data on key marketed and investigational compounds in its oncology, diabetes and cardiovascular franchises, and growth in sales and EPS.
More Pharma News ...
- GlaxoSmithKline statement in response to FDA announcement on TIDE trial
- Abbott Reports Strong Second Quarter Results
- Novartis delivers strong financial performance in second quarter
- Bayer Schering Pharma enters strategic partnership with Hospital in China
- FDA Grants Priority Review Designation to Denosumab
- Mylan to Acquire Bioniche Pharma Global Injectable Pharmaceuticals Business
- Amgen Foundation and Changemakers Launch Global Online Competition to Empower Patients